Publication date: Aug 27, 2024
Hybrid immunity against SARS-CoV-2 has not been well studied in pregnancy. We conducted a comprehensive analysis of neutralizing antibodies (nAb) and binding antibodies in pregnant individuals who received mRNA vaccination, natural infection, or both. A third vaccine dose augmented nAb levels compared to the two-dose regimen or natural infection alone; this effect was more pronounced in hybrid immunity. There was reduced anti-Omicron nAb, but the maternal-fetal transfer efficiency remained comparable to that of other variants. Vaccine-induced nAbs were transferred more efficiently than infection-induced nAbs. Anti-spike receptor binding domain (RBD) IgG was associated with nAb against wild-type (Wuhan-Hu-1) following breakthrough infection. Both vaccination and infection-induced anti-RBD IgA, which was more durable than anti-nucleocapsid IgA. IgA response was attenuated in pregnancy compared to non-pregnant controls. These data provide additional evidence of augmentation of humoral immune responses in hybrid immunity in pregnancy.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Efficiency | Anti |
| Mrna | Antibodies |
| Nucleocapsid | Binding |
| Pregnant | Cov |
| Vaccine | Hybrid |
| Iga | |
| Immunity | |
| Induced | |
| Infection | |
| Nab | |
| Neutralizing | |
| Pregnancy | |
| Pregnant | |
| Sars | |
| Vaccination |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | VO | vaccination |
| disease | MESH | infection |
| disease | VO | vaccine dose |
| disease | VO | dose |
| disease | VO | efficiency |
| disease | VO | vaccine |
| disease | MESH | breakthrough infection |
| disease | VO | effectiveness |
| disease | MESH | COVID 19 |
| disease | VO | population |
| disease | VO | USA |
| disease | MESH | Infectious Diseases |
| disease | VO | effective |
| disease | VO | Glycoprotein |
| drug | DRUGBANK | Coenzyme M |
| disease | VO | vaccinated |
| disease | VO | immunization |
| disease | VO | titer |
| disease | IDO | blood |
| disease | IDO | history |
| disease | IDO | assay |
| drug | DRUGBANK | Proline |
| disease | VO | antibody titer |
| disease | VO | vaccination dose |
| disease | IDO | production |
| disease | IDO | host |
| disease | VO | frequency |
| disease | IDO | cell |
| disease | MESH | mutation rate |
| disease | VO | time |
| disease | VO | gene |
| disease | IDO | infectivity |
| drug | DRUGBANK | Angiotensin II |
| drug | DRUGBANK | Calcium |
| disease | VO | manufacturer |
| disease | MESH | Emergency |
| drug | DRUGBANK | (S)-Des-Me-Ampa |
| disease | VO | vaccine efficacy |
| disease | VO | pregnant women |
| drug | DRUGBANK | Modafinil |
| disease | VO | unvaccinated |